While there were no statistically significant effects of GSK1070806 doses on FPG levels, or glucose, insulin, and C-peptide weighted mean AUC(0–4 hours) over placebo, it should be noted that the trial was not formally powered to detect statistically significant differences in these measures between GSK1070806 and placebo, as the sample size was selected to allow preliminary characterization of efficacy, safety, and tolerability in obese patients with T2DM, and to investigate the effect on PD assessment and biomarkers. Here, INS is linked to type 2 diabetes mellitus.